[Treatment of focal dystonia with botulinic toxin].
F.J. Gracia, Castillo Lc
Abstract
F.J. Gracia, Castillo Lc
Abstract
Dystonia is a neurologic disease characterized by involuntary repetitive muscular contractions which frequently causes torsion, spasmodic movements or abnormal postures. Pharmacologic and surgical treatment had been unsatisfactory in the majority of the cases. Intramuscular botulinic toxin application in focal dystonia disorders, achieve relief in approximately 90% of the cases by quimiodenervation. We included 35 patients with focal dystonia treated between November 1994 through June 1996: 14 facial hemispasm, nine blepharospasm, five cervical dystonia, two writer's cramps, one oromandibular dystonia and four patients with mixed focal dystonia. Improvement between 50-90% was observed in 32/34 (94%) of the patients; one case (2.8%) with therapeutic failure and one case (2.8%) never returned to quantify the response. Actually, botulinic toxin is the first choice treatment of focal dystonia and other diseases related to involuntary muscle spasm.
OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Dystonia is a neurologic disease characterized by involuntary repetitive muscular contractions which frequently causes torsion, spasmodic movements or abnormal postures. Pharmacologic and surgical treatment had been unsatisfactory in the majority of the cases. Intramuscular botulinic toxin application in focal dystonia disorders, achieve relief in approximately 90% of the cases by quimiodenervation. We included 35 patients with focal dystonia treated between November 1994 through June 1996: 14 facial hemispasm, nine blepharospasm, five cervical dystonia, two writer's cramps, one oromandibular dystonia and four patients with mixed focal dystonia. Improvement between 50-90% was observed in 32/34 (94%) of the patients; one case (2.8%) with therapeutic failure and one case (2.8%) never returned to quantify the response. Actually, botulinic toxin is the first choice treatment of focal dystonia and other diseases related to involuntary muscle spasm.
Key concepts: Blepharospasm, Focal dystonia, Dystonia, Cervical dystonia, Medicine, Botulinum toxin, Movement disorders, Facial muscles